Cargando…

Residual renal function in chronic dialysis is not associated with reduced erythropoietin-stimulating agent dose requirements: a cross-sectional study

BACKGROUND: Anaemia is a very common problem in patients with end-stage kidney disease (ESKD) and the use of erythropoietin-stimulating agents (ESA) has revolutionised its treatment. Residual renal function (RRF) is associated with a reduction in ESA resistance and mortality in chronic dialysis. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louw, Elizabeth Helene, Chothia, Mogamat-Yazied
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702117/ https://www.ncbi.nlm.nih.gov/pubmed/29178879 http://dx.doi.org/10.1186/s12882-017-0752-x

Ejemplares similares

The association between office blood pressure and fluid status using bioimpedance spectroscopy in stable continuous ambulatory peritoneal dialysis patients
por: Slabbert, Adriaan, et al.
Publicado: (2022)

Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2018)

Distal renal tubular acidosis in a patient with Hashimoto’s thyroiditis: a case report
por: Mhlana, Nontembiso, et al.
Publicado: (2023)

Aspergillus fumigatus: a rare cause of peritonitis in a peritoneal dialysis patient (a case report)
por: Engelbrecht, Amori, et al.
Publicado: (2022)

High-output cardiac failure due to multiple femoral arteriovenous fistulae
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2020)

Hypodipsic-hypernatremia syndrome in an adult with polycythemia: a case report
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2018)

The frequency of acid-base disorders on admission to the intensive care and its association with in-hospital outcome, Cape Town, South Africa: a retrospective cohort study
por: Sithole, Nokwanda, et al.
Publicado: (2022)

A method comparison study of a point-of-care blood gas analyser with a laboratory auto-analyser for the determination of potassium concentrations during hyperkalaemia in patients with kidney disease
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2020)

Intradialytic hypertension during chronic haemodialysis and subclinical fluid overload assessed by bioimpedance spectroscopy
por: Sebastian, Sajith, et al.
Publicado: (2016)

Hypoglycaemia due to insulin therapy for the management of hyperkalaemia in hospitalised adults: A scoping review
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2022)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients
por: Bae, Myoung Nam, et al.
Publicado: (2015)

Outcomes of hospitalised patients with hyperkalaemia at a South African tertiary healthcare centre
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2022)

Incidence, microbiological aspects and associated risk factors of catheter-related bloodstream infections in adults on chronic haemodialysis at a tertiary hospital in Uganda
por: Nanyunja, Doreen, et al.
Publicado: (2022)

Do diabetic dialysis patients require more or less of erythropoietin?
por: Mitwalli, Ahmad, et al.
Publicado: (2013)

Effect of erythropoietin-stimulating agent on uremic inflammation
por: Tanaka, Yuri, et al.
Publicado: (2012)

Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?
por: Gabutti, Luca, et al.
Publicado: (2011)

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
por: Inrig, Jula K, et al.
Publicado: (2011)

Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice
por: Gaipov, Abduzhappar, et al.
Publicado: (2020)

Residual renal function in incremental dialysis
por: Tattersall, James
Publicado: (2018)

Incremental Peritoneal Dialysis May be Beneficial for Preserving Residual Renal Function Compared to Full-dose Peritoneal Dialysis
por: Lee, Yeonhee, et al.
Publicado: (2019)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021)

Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure
por: Jeong, Hye Yun, et al.
Publicado: (2017)

Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review
por: Damarlapally, Nanush, et al.
Publicado: (2023)

Neuronal nitric oxide synthase is required for erythropoietin stimulated erythropoiesis in mice
por: Lee, Jeeyoung, et al.
Publicado: (2023)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Effect of membrane dialysis and filtration-sterilization on erythropoietin activity.
por: Gallicchio, V. S., et al.
Publicado: (1981)

A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis
por: Bonafont, Xavier, et al.
Publicado: (2009)

Reduction in new-onset diabetes mellitus after renal transplant with erythropoietin-stimulating agents: a retrospective cohort study
por: Montada-Atin, Tess, et al.
Publicado: (2016)

Erythropoietin and renal protection
por: Baradaran, Azar, et al.
Publicado: (2013)

Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study
por: Io, Hiroaki, et al.
Publicado: (2023)

The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions
por: Palazzuoli, Alberto, et al.
Publicado: (2014)

The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
por: Kim, Seoung Gu, et al.
Publicado: (2009)

Residual Renal Function in Children Treated with Chronic Peritoneal Dialysis
por: Roszkowska-Blaim, Maria, et al.
Publicado: (2013)

Strategies for preserving residual renal function in peritoneal dialysis patients
por: Nongnuch, Arkom, et al.
Publicado: (2015)

Erythropoietin: a multimodal neuroprotective agent
por: Byts, Nadiya, et al.
Publicado: (2009)

Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation
por: Fujimoto, Daisuke, et al.
Publicado: (2020)

The Predictive Parameters of Erythropoietin Hyporesponsiveness in Patients on Continuous Ambulatory Peritoneal Dialysis
por: Kim, Jeong Ki, et al.
Publicado: (2001)

Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol
por: Strippoli, Giovanni FM
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bbt7ks2tt0n75uobdvqfvhdhhl